LipoNova AG
LipoNova AG: LIPONOVA SIGNS MEMORANDUM OF UNDERSTANDING FOR THE MARKETING OF RENIALE(R)
LipoNova AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Hannover, Germany 27 November 2007 - LipoNova AG (WKN LNAG00) the pioneering developer of Reniale, the world’s first autologous vaccine for non-metastatic renal cell carcinoma (RCC), announced today that it has signed a Memorandum of Understanding (MoU) for the development and marketing of its product candidate Reniale(R) with a respected non-European pharmaceutical company. The MoU provides for milestone payments and ongoing sales-related payments (royalties) for the sale of Reniale(R). LipoNova’s partner is being granted an exclusive licence for a non-European country for this purpose. After conclusion of the agreement, the partner will actively support the international Phase III study and be involved in possible ‘named patients’ programmes. The Executive Board regards the MoU as an important step in the development and marketing of Reniale(R) outside Europe. The MoU confirms that foreign companies are very interested in marketing Reniale(R) and therefore provides further evidence or Reniale’s market potential. LipoNova aims to launch Reniale(R) on other non-European markets. About LipoNova: LipoNova is developing an effective therapy for non-metastatic renal cell carcinoma (RCC), a serious disease with high unmet medical need and are pioneers in the development of autologous tumour vaccines, a new class of compounds for combating diseases of this type. LipoNova has successfully completed a Phase-III clinical study on adjuvant RCC with Reniale(R) their lead product, the world’s first autologous treatment with demonstrated efficacy and safety as an adjuvant therapy in non-metastatic RCC. LipoNova is well positioned to bring Reniale(R) to market with an international Phase III study planned to start 2008 and as this progresses, it will expand its oncology franchise in the short to medium term through partnering, mergers and acquisitions. LipoNova Oliver Keilhack, CFO Tel: +49 (0) 511 54099-610 E-Mail: oliver.keilhack@liponova.de DeFacto Communications Sylvie Berrebi Tel : +44 (0)20 7861 3838 E-mail: s.berrebi@defacto.com 27.11.2007 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: LipoNova AG Feodor-Lynen-Str. 35 30625 Hannover Deutschland Phone: +49 (0)511-54099 0 Fax: +49 (0)511-54099 31 E-mail: info@liponova.de Internet: www.liponova.de ISIN: DE000LNAG002 WKN: LNAG00 Listed: Freiverkehr in Berlin, Düsseldorf, Stuttgart; Entry Standard in Frankfurt End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden